School of Lifesciences, Sejong University, Seoul 05006, Republic of Korea.
Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Pharmacol Ther. 2022 Oct;238:108269. doi: 10.1016/j.pharmthera.2022.108269. Epub 2022 Aug 28.
Mixed lineage kinase 3 (MLK3) is a serine/threonine kinase family member of mitogen activated protein kinase kinase kinases (MAP3Ks). MLK3 has been implicated in the regulation of tumor cell proliferation, differentiation, migration, invasion, and apoptosis depending on the cellular contexts. Notwithstanding the involvement of MLK3 in several cancers, the precise roles of MLK3 are not completely understood. This review evaluates the molecular mechanisms and signaling pathways associated with MLK3, which play a major role in malignancies that include breast, cervical, colorectal, gastric and prostate cancer. Since early detection of cancer is critical, this review discusses the potential of MLK3 as a predictive biomarker, which could likely help in clinical decision-making. Importantly, the efficacy of targeting MLK3 via different therapeutic approaches is also explored.
混合谱系激酶 3(MLK3)是丝氨酸/苏氨酸激酶家族成员中的丝裂原活化蛋白激酶激酶激酶(MAP3Ks)。根据细胞环境的不同,MLK3 参与调节肿瘤细胞的增殖、分化、迁移、侵袭和凋亡。尽管 MLK3 参与了几种癌症,但 MLK3 的具体作用尚未完全了解。本综述评估了与 MLK3 相关的分子机制和信号通路,这些机制和信号通路在包括乳腺癌、宫颈癌、结直肠癌、胃癌和前列腺癌在内的恶性肿瘤中发挥着重要作用。由于癌症的早期检测至关重要,因此本综述讨论了 MLK3 作为预测性生物标志物的潜力,这可能有助于临床决策。重要的是,还探讨了通过不同治疗方法靶向 MLK3 的疗效。